Skip to main content
    C

    Coya Therapeutics, Inc. Common Stock (COYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.02
    +0.02 (+0.67%)

    Market Cap: $70.37M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Coya Therapeutics, Inc. Common Stock (COYA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Coya Therapeutics, Inc. Common Stock (COYA) has a market cap of $70.37M and an enterprise value of $34.57M. It kept -643.45% of revenue as net income over the last 12 months. Its share count is up 40.19% from a year earlier.

    Total Valuation

    Enterprise value is 50.87% below the market cap, as cash exceeds debt.

    Market Cap$70.37M
    Enterprise Value$34.57M
    Latest price (Nov 17, 2026)$3.02

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 24.14% a year over 2 years.

    Shares Outstanding23.46M
    Shares Change (YoY)+40.19%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+24.14%

    Valuation Ratios

    Sales and book value multiples are 15.1x and 2.1x. Its year-end P/S ranged from 12.2x to 24.0x from 2023 to 2025.

    P/S Ratio15.1x
    Forward P/S88.3x
    P/B Ratio2.1x

    Valuation history and multiples

    Price Statistics

    The stock is down 48.55% over 52 weeks and trades 28.61% below its 50-day average.

    Beta (1Y)1.83
    52-Week Change-48.55%
    1-Month Change-28.10%
    3-Month Change-39.24%
    6-Month Change-33.92%
    Total Return (1Y)-48.55%
    Total Return (3Y CAGR)-17.35%
    Return vs SPY (1Y)-62.53%
    Max Drawdown (1Y)-56.84%
    Max Drawdown (3Y)-72.42%
    Sharpe Ratio (1Y)-1.15
    Correlation with SPY (1Y)0.40
    50-Day Average$4.23
    200-Day Average$4.55
    52-Week Range$2.72 to $6.62
    RSI (14 Days)33.1
    Average Volume (20 Days)179.57K

    Price chart

    Financial Position

    Current assets cover 7.24x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio7.24x
    Quick Ratio7.24x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -89.88% and return on assets is -76.74% over the last 12 months.

    Return on Equity (ROE)-89.88%
    Return on Assets (ROA)-76.74%
    Return on Capital Employed (ROCE)-88.93%
    ROA (5Y Average)-68.67%
    Asset Turnover0.13x

    Scores

    COYA has an Altman Z-Score of 2.93, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score2.93
    Altman Z ZoneGrey
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $4.69M over the last 12 months is up 17.59% from the 12 months before.

    Revenue$4.69M
    Revenue Growth (YoY)+17.59%
    Gross Profit$4.69M
    Operating Income-$31.67M
    Pretax Income-$32.28M
    Net Income-$30.17M
    EBITDA-$30.15M
    EBIT-$30.17M
    Reported EPS (TTM)-$1.39

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 85.38% of the $39.32M in total assets.

    Cash and Equivalents$35.80M
    Total Debt$0
    Net Cash$35.80M
    Net Cash Per Share$1.53
    Working Capital$33.68M
    Shareholder Equity$33.57M
    Book Value Per Share$1.43
    Total Assets$39.32M
    Total Liabilities$5.75M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$21.83M
    FCF Per Share-$0.93
    Depreciation and Amortization$15.26K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -675.34%.

    Gross Margin100.00%
    Operating Margin-675.34%
    Pretax Margin-688.51%
    Net Margin-643.45%
    EBITDA Margin-643.06%
    EBIT Margin-643.38%

    Growth

    Book Value Per Share Growth (2Y CAGR)-14.35%
    Tangible Book Per Share Growth (2Y CAGR)-14.35%

    Revenue and profit by year

    Dividends and Yields

    COYA does not pay a dividend.

    Buyback Yield-44.19%
    Shareholder Yield-44.19%

    Peer Position

    Against 4 similar companies, COYA has the 2nd highest P/S.

    P/S Ratio15.1x vs 7.0x median
    Revenue Growth (Trailing 4 Quarters, YoY)+17.59% vs -42.77% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -20.36% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-20.36%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About COYA

    What is COYA's market cap?

    Coya Therapeutics, Inc. Common Stock has a market cap of $70.37M. Its enterprise value, which adds debt and subtracts cash, is $34.57M.

    How many shares of COYA are outstanding?

    Coya Therapeutics, Inc. Common Stock has 23.46M shares outstanding. The count is up 40.19% from a year earlier.

    Does COYA pay a dividend?

    No. Coya Therapeutics, Inc. Common Stock does not pay a dividend.

    How much debt does COYA have?

    Coya Therapeutics, Inc. Common Stock has $0 of total debt and $35.80M of cash and equivalents, a net cash position of $35.80M.